1. South Korea Stocks

  2. •

    Health services

  3. •

    Medical/Nursing services
Penetrium Bioscience Inc.

Penetrium Bioscience Inc.

KKRX:187660
5,770.00
KRW
+140.00
(+2.49%)
-289.93EPS
296.89BMarket Cap
Penetrium Bioscience Inc.
KRX:187660
(Korea Stock Exchange)

Recent

price

5,770.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
43,883.72
302.81
359.58
329.7
316.55
307.96
217.62
189.04
153.01
Revenue per Share
8,896.88
22.67
103.45
45.35
5.67
-66.33
-448.78
-302.32
-300.06
Basic EPS, GAAP
10,672.8
35.65
143.6
-9.74
-14.21
-82.68
-321.33
-106.99
-78.48
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
82.33
235.58
310.24
726.59
677.56
606.32
152.35
371.24
395.55
Book Value per Share
80.36
233.85
308.65
724.8
655.82
582.17
147.09
368.07
393
Tangible Book Value per Share
- -
34
36
42
47
45
45
49
55
Basic Weighted Avg Shares
2,389
10,206
13,120
13,978
14,883
13,790
9,745
9,273
8,344
Sales/Revenue/Turnover
4.18
8.34
26.91
14.96
-5.07
-13.86
-163.49
-79.55
-80.3
Operating Margin (%)
16
499
534
702
1,086
1,559
1,589
1,113
1,000
Depreciation Expense
484
764
3,775
1,923
267
-2,970
-20,096
-14,830
-16,364
Net Income, GAAP
16.74
25.15
22.42
20.42
176.91
- -
- -
- -
- -
Effective Tax Rate (%)
20.27
7.49
28.77
13.75
1.79
-21.54
-206.22
-159.92
-196.11
Profit Margin (%)
4,184
10,066
12,986
30,959
26,382
10,259
-9,226
-1,146
-4,784
Working Capital
- -
- -
20
10
251
267
449
31
202
LT Debt
3,912
10,958
14,413
33,457
30,710
27,128
6,629
21,527
22,936
Total Equity
- -
8.14
20.35
6.74
1.78
- -
- -
- -
- -
Return on Invested Capital (%)
- -
11.76
30.75
8.9
0.62
- -
- -
- -
- -
Return on Capital (%)
- -
10.4
29.92
8.02
0.83
-10.33
-118.31
-104.62
-104.28
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,430
5,327
5,243
LT Borrowings
- -
- -
- -
LT Finance Leases
31
20
202
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
58
Market Capitalization
130,384
605,352
296,889

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,347
5,969
4,511
Cash, Cash Equivalents & STI
4,846
2,314
501
Accounts Receivable, Net
1,104
619
528
Inventories
- -
- -
- -
Total Current Liabilities
10,493
9,927
9,295
Payables & Accruals
- -
- -
- -
ST Debt
5,430
5,327
5,243
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
52.29%
224.76%
Free Cash Flow
- -
126.61%
-63.53%
Net Income, GAAP
- -
-159.88%
-26.21%
Sales/Revenue/Turnover
- -
-5.7%
-4.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,933
2,627
2,045
2,141
9,745
2025
2,213
2,524
2,607
1,930
9,273
2026
1,692
2,116
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-31.18
-278.69
-79.62
-59.28
-448.78
2025
-81.25
40.62
-166.12
-83.14
-302.32
2026
-32.19
-27.57
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Hims & Hers Health, Inc. (NYSE:HIMS)
Mobile-health Network Solutions (NASDAQ:MNDR)
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)
Dr. Lal PathLabs Limited (NSE:LALPATHLAB)
Tenon Medical, Inc. (NASDAQ:TNON)
Teladoc Health, Inc. (NYSE:TDOC)
Business
Penetrium Bioscience Inc. is a South Korea-based clinical-stage biopharmaceutical company that specializes in the discovery, research, and development of novel biotherapeutics and multi-target fusion proteins for the treatment of metabolic disorders, immuno-oncology, and autoimmune diseases. The company develops therapeutic assets utilizing its proprietary platform technologies, primarily the NTIG (Non-covalent Triple Immunoglobulin) platform, which facilitates the design of long-acting, multi-specific fusion proteins with customizable pharmacokinetics and enhanced tissue penetration capabilities. The company operates through integrated biopharmaceutical research and drug development segments, offering an investigational pipeline that includes: PG-102, a long-acting dual GLP-1 and GLP-2 receptor agonist developed for obesity, type 2 diabetes, and metabolic dysfunction-associated steatohepatitis (MASH); PG-101, an engineered interleukin-2 (IL-2) fusion protein targeting advanced solid tumors and refractory cancers; PG-105, a multi-specific fusion protein candidate for immuno-oncology applications; and PG-110, an investigational biologic candidate directed at chronic inflammatory and autoimmune conditions. In addition to internal pipeline advancement, the company provides collaborative research, preclinical candidate optimization, protein engineering, and technology out-licensing services to international biotechnology and pharmaceutical partners. In recent corporate developments, Yuhan Corporation completed a strategic equity investment to become the company's largest shareholder, establishing a joint development partnership focused on co-advancing the PG-102 metabolic pipeline and next-generation dual-target biologics. The company has also progressed PG-102 through Phase 1 clinical trial evaluations to assess safety, pharmacokinetics, and glycemic modulation, while continuing to expand its international patent portfolio covering multi-target fusion constructs and drug delivery mechanisms across North America, Europe, and Asia. Founded in 1998, Penetrium Bioscience Inc. is headquartered in Seoul, South Korea.